It is proposed that structure-based optimization of 1 may be
achieved by altering the nature of the substituent in position 7. As
such, a representative library of compounds 1 for SAR studies is
required, and these studies should provide compounds with improved
pharmacological profile that have the potential to be taken
forward as drug leads. Ethyl 4-chloro-7-iodoquinoline-3-
carboxylate (2, CIQCeScheme 2), proved to be instrumental as intermediate
for easy access to a range of new quinolone 3-esters 1.